Claude Nogard Presents Ergosuture at LSI USA ‘23

Transcription

Claude Nogard  0:04  

So my name is Claude Nogard, CEO and co founder of Ergosuture. Six years ago, we founded the company with one objective in mind how to simplify suturing to be more efficient, the out and so is here. This is a first order based drink system ever invented to use off the shelf needles 20 years ago, the DaVinci. And The Wiz came with so many degrees of freedom and wanting to use the next degree of freedom with the automated system. This is a platform that is transformative because it changed the relationship between needle in the driver with also agnostics, we can mount this platform as I was meant to be unto you across every platform from a handheld to robotic, even transcatheter applications. So you might want to wait the market is a tale of two or two stories in US primarily in handheld devices, you know     or straight shaft in the US with liquidation, we do expect that with instrumental presenting more than 58% of the market, there will be an opening for for companies to collaborate with us to actually improve the scoring system. And we do believe in we're already working on that aluminum surgery might be our entry point suturing system that can teach you how tissues are not ready yet, especially for the visual graph. And that's very much why we developed our technology, our obvious platform, we will actually develop that to work across all platforms, I will present to you the first product straight shaft. But what we see collaborating with companies to include that into robotic platform, as well as translate applications thinks about mitral valve repair, PA for repair. That's the future. So this platform, as I said is agnostic. It will work in soft tissue initially. So looking at a OPGI or intra abdominal surgeries colorectal, biotic, urology, and gynecology. It's a platform that you know that will enter initially laparoscopic surgery. So we did our market research. And we found out that, you know, surgeons still seek better steering system that are easier on the training side can allow to secure faster, but more importantly, improve economic and better access in how to reach places. So this is a cornerstone of our technology, improved needle control, isolation of movement, and reduce your handing, you know, steps that could dock time, as you can see in that video here, that very much a person suturing here, you're an engineer to train himself in a week. So he's not a surgeon. And that's what this platform gives you to you. So this is our first device. This is you know, the Dragon World five millimeter device composed primarily, as you can see the hand handle that is fully suitable. That is airtight is a device that can be used for more than 200 surgeries can be sterilized. We're attached to it to single use distal end, which is primarily our business model that actually in SQS, will be used multiple times. This year, we did multiple changes, we actually shrank the size of the handles so you can adapt to female surgeons. And we also included in on the side, as you can see at the top the directional switch, supporting the surgeon the ability to understand, you know very intuitively where the direction reward is doing surgeries. And so these are the key benefit here starting from the US single use device. But these distal ends were built to be used for more than 10 surgeries. And so what we'll do for next US is adding a flushing port to actually adapt to the market. The core benefit of what they showed in the video are here, self righting, and we push the needle you can do that in one movement. That's something that doesn't require the use of grasper and that shut down cut down to check time tremendous. Ability to control the needle speed. You can't do that with a robot why now, we can do that why now with this device, you can actually accelerate or decelerate the speed of needles with tissues, you can control the isolation of this needle. So when you remove it from tissue, you can minimize the damage. And then last but not least, for the five millimeter device, we included something which is a little guide. And the objective here was to enable the surgeons to basically find the waters without ever looking at the device. So that basic naturally plays a wound between dollars and was the core benefits. At launch, we focus primarily on that suturing tie. Everybody has a claim of fame for that. But this is our core that we will will you know we into that we have done a lot of research and found out which surgeons tend to benefit tremendously of the device. You can see here is 85% suturing time reduction, at the 30 minutes of training for every surgeon experts have some benefit, but it's quite well generally stage. If you look at the competition, we have some competitors. But you can see fairly quickly that we can work across all platforms. We can use off the shelf windows, we can use proprietary needles, and we can be adapted even to robotic platforms. And so the future is already here. As I mentioned to you, we're already collaborating with some robotic companies. And we're inviting mobile tech companies to talk to us and this is what you can see here. So we try to understand the benefit for the product for both and the key thing we came out is that we're going to develop only for them. We have to consider The other challenges they are facing. And so the key thing that we have developed for them is your ability to use our device, not only an Intel driver, but also the grasper and dissector. So we have a system when we spoke yesterday, which is allowing them to force open and close the jaws. We also allow them the ability to very, very good grips in strengths, which allowing them to do dissection without damaging tissues. And last but not least, this is degrees of freedom, we take away the twerking of the waist. So even though we're about at this stage, we believe that the time the time gain will be tremendous at this level. Pattern wise, we have more than 20 patterns across the board, from the Wallabies system to our needles individually to our Endoplasty Ring that we are developing. Currently, we have very expensive team that has more than 20 years of experience, on average, that have been involved in with with startups with exit. We were quite busy from the last time I talked to you. We hired we internalize completely our r&d, we actually we develop our product from the eight to five millimeter. And we're currently design freeze here. We we basically internalize our curricular applications. And last but not least, we need our first POC for the surgery platform. I don't mean old surgery platform. The question is, why are we going to win when everybody has failed so far? The key thing here is suturing time. That's very much where clinical trials are designed for the constructivist standpoint. But we also have the only ones who are covered to patent for the entire technology platform with reusable model for this blade and the actual distance. And something important, the fact that we can use that device across all platforms. So I mentioned to you that you know, contrary to our competition, our innovation is that very much objective here, that is nothing else is not in the shaft is not the handle, which means that we can compete and collaborate with everybody. And the objective for us is not to record the market from, you know, device standpoint, but flat teams, purses, wallets, and that's pretty much a robbery. But anyhow, our revenue model will be based on needle. And basically shooting an insurgent says our company will actually evolve with time, if this company was to be made, you know, integrated with time that will a $1 billion company within 10 years. That won't be the case, we do believe that we be co slicing this business as we go through the market. So this is where we are right now we are closing our $5 million seed. And we are preparing for 20 million series A by now this year for launch in the US. So I mentioned to you that you know we have technology which is transformative, which quite unique actually from business standpoint for investors, because we understand that all partners and activity are not mutually consistent. So we'll be able to work in slice that business with our investors to make it viable for them. So we already raised $6 million to serve in the network. We are currently closing our $5 million. And this is primarily to close our r&d manufacturing capabilities. And last but not least, we are very actively looking for partnership in robotic platforms. So if you're interested, please talk to me. We are looking forward to basically work with you to advance the system. Thank you